Adamas Pharmaceuticals Inc. buy klostergang
Start price
08.09.17
/
50%
€19.96
Target price
08.08.19
€55.92
Performance (%)
-72.87%
End price
08.08.19
€5.42
Summary
This prediction ended on 08.08.19 with a price of €5.42. Massive losses of -72.87% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Adamas Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | -3.033% | -0.013% | 11.953% | 15.609% |
iShares Nasdaq 100 | -3.554% | -2.546% | 30.128% | 44.540% |
iShares Nikkei 225® | -3.938% | 2.183% | 11.741% | 8.345% |
iShares S&P 500 | -1.517% | -0.882% | 25.752% | 42.388% |
Comments by klostergang for this prediction
In the thread Adamas Pharmaceuticals Inc. diskutieren
klostergang stimmt der Buy-Einschätzung von klostergang zu
klostergang stimmt am 08.09.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 22$ zu.
Überschrift: Adamas's ADS-5102 could become the first FDA approved drug for Parkinson's disease
The comment has been deleted
Stopped prediction by klostergang for Adamas Pharmaceuticals Inc.
Adamas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.28
15.03.20
15.03.20
€5.00
04.11.21
04.11.21
87.72%
17.06.21
17.06.21
Adamas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.50
01.10.19
01.10.19
€9.00
19.12.19
19.12.19
-24.89%
19.12.19
19.12.19
Adamas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€12.89
20.08.17
20.08.17
€19.84
04.09.17
04.09.17
48.99%
04.09.17
04.09.17